Patents Examined by Tara L Martinez
-
Patent number: 11965011Abstract: An antitumor peptide provided according to the present invention includes (1) an S1PR-TM related sequence; and (2) an amino acid sequence functioning as a cell penetrating peptide; wherein the total number of amino acid residues is 100 or less.Type: GrantFiled: June 28, 2022Date of Patent: April 23, 2024Assignees: Toagosei Co., LTD, National University Corporation Nagoya UniversityInventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Makoto Sawada
-
Patent number: 11964000Abstract: Provided herein are compositions comprising peptide amphiphiles, glycosylated peptide amphiphiles (GPAs), supramolecular nanostructures assembled therefrom, and methods of use thereof. The peptide amphiphiles described herein may extend the half-life of bone morphogenic proteins, promote cell differentiation, suppress proliferation, and increase chemosensitivity of cells. Accordingly, the compositions described herein may be used for cancer treatment methods. In particular, provided herein are bone morphogenic proteins bound to peptide amphiphiles and glycosylated peptide amphiphiles or composites thereof, and methods of use of the same for the treatment of cancer. Also, provided herein are bone morphogenic proteins bound to peptide amphiphiles and glycosylated peptide amphiphiles or composites thereof, and methods of use of the same in a combinatorial approach together with chemotherapeutic medications for the treatment of cancer.Type: GrantFiled: April 12, 2021Date of Patent: April 23, 2024Assignee: Northwestern UniversityInventors: Samuel I. Stupp, Mark Trosper McClendon, Guifa Xi, Bo Timmy Bjoern Fyrner, Cara S. Smith, Nicholas A. Sather
-
Patent number: 11952407Abstract: Preparations including recombinant FSH (rFSH).Type: GrantFiled: April 30, 2021Date of Patent: April 9, 2024Assignee: FERRING INTERNATIONAL CENTER S.A.Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
-
Patent number: 11925724Abstract: Provided are novel compounds and uses thereof in preventing antifouling by unicellular organisms and in attracting cells from multicellular organisms.Type: GrantFiled: September 7, 2016Date of Patent: March 12, 2024Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Meital Reches, Sivan Yuran
-
Patent number: 11925192Abstract: The present invention concerns a beverage having water and a concentration range of about 0.001 grams per liter to 8.44 grams per liter of collagen, wherein the collagen is hydrolyzed. The collagen concentration range may be between 1 milligram per liter to about 8440 milligram per liter or 1 parts per million to about 8440 parts per million. The hydrolyzed collagen has collagen peptides. The collagen peptides are produced through hydrolysis of a plurality of collagen sources. The plurality of collagen sources are derived from at least one of animal raw materials, animals raised in non-organic or organic farms, animals from various animal species and various parts of the animal carcass. The water may be comprised of at least one of tap water, spring or mineral water, and iceberg or glacier water.Type: GrantFiled: December 15, 2015Date of Patent: March 12, 2024Assignee: WELLDRINKS LTDInventors: Alexander Evgenievich Kamcharov, Martin Seele, Tihomir Georgiev Yovchev, Yavor Nikolaev Draganov, Jurgen Pieck, Christian Schrobsdorff
-
Patent number: 11912748Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: May 7, 2021Date of Patent: February 27, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 11912749Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: November 5, 2021Date of Patent: February 27, 2024Assignee: Immatics Biotechnologies GMBHInventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 11878047Abstract: Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.Type: GrantFiled: January 3, 2019Date of Patent: January 23, 2024Assignee: Sapience Therapeutics, Inc.Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo
-
Patent number: 11879021Abstract: Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of CD36-related diseases, disorders or conditions in a subject, such as atherosclerosis and age-related macular degeneration.Type: GrantFiled: June 28, 2017Date of Patent: January 23, 2024Inventors: William D. Lubell, Huy Ong, Jinqiang Zhang, Dilan Mukandila Mulumba, Sylvie Marleau, Ragnhild Gaard Ohm, Ahsanullah, Samy Omri, Ramesh Chingle
-
Patent number: 11865161Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.Type: GrantFiled: April 19, 2019Date of Patent: January 9, 2024Assignee: Hamlet Pharma ABInventors: Catharina Svanborg, Manoj Puthia, Chin Shing Ho
-
Patent number: 11845785Abstract: Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.Type: GrantFiled: November 18, 2020Date of Patent: December 19, 2023Assignee: University of Pittsburgh—Of the CommonwealthSystem of Higher EducationInventors: Mark T. Gladwin, Jesus Tejero Bravo
-
Patent number: 11833191Abstract: The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.Type: GrantFiled: October 28, 2020Date of Patent: December 5, 2023Assignee: Dignity HealthInventor: Jiong Shi
-
Patent number: 11833187Abstract: Sortilin is a sorting receptor that directs target proteins to the secretary or endocytic compartments of cells that is found in both extracellular vesicles and cells. Provided herein are methods and compositions for decreasing or inhibiting trafficking of sortilin to an extracellular vesicle, for example by inhibiting the formation of intermolecular sortilin dimers.Type: GrantFiled: October 23, 2018Date of Patent: December 5, 2023Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Shinsuke Ito, Elena Aikawa, Masanori Aikawa
-
Patent number: 11814410Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: November 2, 2018Date of Patent: November 14, 2023Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel R. Hostetter, Olga Vasiljeva, Jeanne Grace Flandez
-
Patent number: 11793858Abstract: Antimicrobial compositions having bactericidal activity are described. Also described is a method of treating bacterial infections using compositions comprising antimicrobial peptides or variants thereof.Type: GrantFiled: April 15, 2019Date of Patent: October 24, 2023Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: C. Cheng Kao, Antonio Cembellin Prieto, Dean Rowe-Magnus
-
Patent number: 11793855Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.Type: GrantFiled: January 14, 2019Date of Patent: October 24, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 11780881Abstract: The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells. The compounds can target proteins in the DNA damage repair pathway leading to a decrease in DNA damage repair and cell death.Type: GrantFiled: May 18, 2020Date of Patent: October 10, 2023Assignee: SYNTHEX, INC.Inventors: Charly Chahwan, Maria Soloveychik
-
Patent number: 11771773Abstract: Disclosed are a GLP-1-mimicking pharmaceutical composition for treating type 2 diabetes and a preparation method thereof, wherein the pharmaceutical composition contains polyethylene glycol loxenatide, a physiologically acceptable buffer with the pH of 3.0-7.0, and pharmaceutically acceptable excipients. The pharmaceutical composition has good drug stability.Type: GrantFiled: October 16, 2017Date of Patent: October 3, 2023Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Inventors: Li Dong, Ge Wang, Di Hu, Yundong Sun, Hengli Yuan
-
Patent number: 11753446Abstract: Beta-hairpin peptidomimetics of the general formula (I), cyclo[P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-T1-T2], and pharmaceutically acceptable salts thereof, with P1 to P12, T1 and T2 being elements as defined in the description and the claims, have Gram-negative antimicrobial activity to e.g. inhibit the growth or to kill microorganisms such as Klebsiella pneumoniae and/or Acinetobacter baumannii and/or Escherichia coli. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: GrantFiled: April 8, 2020Date of Patent: September 12, 2023Assignee: POLYPHOR AGInventors: Daniel Obrecht, Anatol Luther, Francesca Bernardini, Peter Zbinden, Sophie Barthelemy, Alexander Lederer
-
Patent number: 11738070Abstract: Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.Type: GrantFiled: November 11, 2020Date of Patent: August 29, 2023Assignee: The Regents of the University of CaliforniaInventor: Dena Dubal